ir.amicustherapeutics.com ir.amicustherapeutics.com

ir.amicustherapeutics.com

Amicus Therapeutics, Inc. - Investor Relations

At the forefront of therapies for rare and orphan diseases. Welcome from chairman and CEO. Protein misfolding and disease. Posters, abstracts and publications. Patient advocacy at amicus. As a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl). In combination with ERT for Pompe disease. View all ». Aug 5, 2015. Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates. Jul 29, 2015. View all ».

http://ir.amicustherapeutics.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.AMICUSTHERAPEUTICS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

May

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.4 out of 5 with 14 reviews
5 star
8
4 star
4
3 star
2
2 star
0
1 star
0

Hey there! Start your review of ir.amicustherapeutics.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

CONTACTS AT IR.AMICUSTHERAPEUTICS.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Amicus Therapeutics, Inc. - Investor Relations | ir.amicustherapeutics.com Reviews
<META>
DESCRIPTION
At the forefront of therapies for rare and orphan diseases. Welcome from chairman and CEO. Protein misfolding and disease. Posters, abstracts and publications. Patient advocacy at amicus. As a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl). In combination with ERT for Pompe disease. View all ». Aug 5, 2015. Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates. Jul 29, 2015. View all ».
<META>
KEYWORDS
1 share
2 about us
3 programs
4 science and technology
5 patient advocacy
6 clinical studies
7 investors
8 collaborations
9 news and events
10 overview
CONTENT
Page content here
KEYWORDS ON
PAGE
share,about us,programs,science and technology,patient advocacy,clinical studies,investors,collaborations,news and events,overview,leadership,amicus belief statement,careers,development pipeline,fabry disease,pompe disease,preclinical programs,resources
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Amicus Therapeutics, Inc. - Investor Relations | ir.amicustherapeutics.com Reviews

https://ir.amicustherapeutics.com

At the forefront of therapies for rare and orphan diseases. Welcome from chairman and CEO. Protein misfolding and disease. Posters, abstracts and publications. Patient advocacy at amicus. As a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl). In combination with ERT for Pompe disease. View all ». Aug 5, 2015. Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates. Jul 29, 2015. View all ».

INTERNAL PAGES

ir.amicustherapeutics.com ir.amicustherapeutics.com
1

SEC Filings - Amicus Therapeutics

http://ir.amicustherapeutics.com/sec.cfm

Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Annual Reports and Proxies. Sign Up for Email Alerts. All Filings (excluding Section 16). Aug 26, 2016. Aug 23, 2016. Aug 19, 2016. Aug 10, 2016. Aug 9, 2016. Aug 9, 2016. Aug 8, 2016. Aug 8, 2016. Jul 29, 2016. Jul 29, 2016. 10 results per page. 25 results per page. 50 results per page.

2

Amicus Therapeutics to Announce Second Quarter 2015 Financial Results on August 5, 2015 (NASDAQ:FOLD)

http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=924410

Jul 29, 2015. Amicus Therapeutics to Announce Second Quarter 2015 Financial Results on August 5, 2015. CRANBURY, N.J. July 29, 2015. Nasdaq:FOLD) today announced a conference call and live audio webcast on. Wednesday, August 5, 2015. To discuss financial results for the second quarter ended. June 30, 2015. The call will be hosted by. John F. Crowley. By dialing 877-303-5859 (U.S./. A live audio webcast can also be accessed via the Investors section of the. August 5, 2015. Nasdaq:FOLD) is a biopharmaceuti...

3

Senior Management Team - Amicus Therapeutics

http://ir.amicustherapeutics.com/management.cfm

Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Annual Reports and Proxies. Sign Up for Email Alerts. John F. Crowley. Chairman and Chief Executive Officer. Senior Vice President, International. Kurt J.W. Andrews. Senior Vice President, Human Resources. Mr Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign. William D. "Chip" Baird, III. Jay A Barth M.D. Bradley L. Campbell.

4

Amicus 2Q Results Conference Call and Webcast - Amicus Therapeutics

http://ir.amicustherapeutics.com/eventdetail.cfm?EventID=163327

Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Annual Reports and Proxies. Sign Up for Email Alerts. Amicus 2Q Results Conference Call and Webcast. Aug 5, 2015.

5

Investor Relations - Amicus Therapeutics

http://ir.amicustherapeutics.com/index.cfm

Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Annual Reports and Proxies. Sign Up for Email Alerts. A passionate team with a purpose. As a monotherapy for Fabry disease, SD-101. For Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders. Aug 10, 2016. Aug 9, 2016. View all press releases ». Jul 11, 2016.

UPGRADE TO PREMIUM TO VIEW 8 MORE

TOTAL PAGES IN THIS WEBSITE

13

LINKS TO THIS WEBSITE

amicustherapeutics.com amicustherapeutics.com

Amicus Therapeutics - About / Management

http://www.amicustherapeutics.com/about/mgmt.asp

Protein Misfolding and Disease. Proposed Mechanism of Action. John F. Crowley, J.D., M.B.A. President and Chief Executive Officer. The Wall Street Journal. And on The Today Show, CNBC and The Paula Zahn Show. Mr Crowley is a commissioned officer in the United States Navy Reserve (active). Donald J. Hayden, Jr. Mr Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University. Matthew R. Patterson. James E. Dentzer. David J. Lockhart, Ph.D. Dr David Lockhart joi...

UPGRADE TO PREMIUM TO VIEW 7 MORE

TOTAL LINKS TO THIS WEBSITE

8

SOCIAL ENGAGEMENT



OTHER SITES

ir.americanrealtycapitalproperties.com ir.americanrealtycapitalproperties.com

IRWeblink

Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.

ir.americanrenal.com ir.americanrenal.com

American Renal

Skip to main content. Home and Peritoneal Dialysis. Take good care of the patients and the financial success will follow. Enable the nephrologist to practice as he/she sees appropriate. Provide the nephrologist the autonomy to make operational decisions. Acknowledge that facility staff members are a critical and valuable asset. Do everything possible to hire and retain the best possible staff. Listen to the practitioners and provide the tools needed to take excellent care of their patients. Nov 11, 2016.

ir.ameriprise.com ir.ameriprise.com

Ameriprise Investor Relations

Skip to top site navigation. 21,930.11 ($M). 065) - (0.53) %. As of August 7, 2015 -. Minimum 20 minute delay. Minimum 20 minute delay. Q2 2015 Long Term Care Review and Other Items. Second Quarter 2015 Earnings Conference Call. Thursday, July 23, 2015. 2014 Online Annual Report. 2014 Annual Report (PDF). Q2 2015 Earnings Release. Q2 2015 Statistical Supplement. Columbia Threadneedle Investments Hires Jim Bumpus to Lead U.S. National Sales. Ameriprise Financial Declares Regular Quarterly Dividend. Electr...

ir.amerisbank.com ir.amerisbank.com

Ameris Bank: your community bank for free checking, online checking and banking services.

Ameris Bank Investor Relations. Deposit and Loan Composition. News and Market Data. Sign in to your account. Ameris Bank Credit Card. Don't have internet banking? Ameris Bank Investor Relations. To learn more about how we can help you expand your financial possibilities, visit one of our locations or continue exploring our site. As of August 7, 2015. Minimum 20 minute delay. Ameris Bancorp Reports Financial Results For Second Quarter 2015. Ameris Bancorp Announces Completion Of Branch Acquisition.

ir.amicusrx.com ir.amicusrx.com

Investor Relations - Amicus Therapeutics

Welcome from Chairman and CEO. Epidermolysis Bullosa (EB) Program. Patient Advocacy at Amicus. Grants and Charitable Donations. Annual Reports and Proxies. Sign Up for Email Alerts. Annual Reports and Proxies. Sign Up for Email Alerts. A passionate team with a purpose. As a monotherapy for Fabry disease, SD-101. For Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders. Apr 6, 2017. Apr 3, 2017.

ir.amicustherapeutics.com ir.amicustherapeutics.com

Amicus Therapeutics, Inc. - Investor Relations

At the forefront of therapies for rare and orphan diseases. Welcome from chairman and CEO. Protein misfolding and disease. Posters, abstracts and publications. Patient advocacy at amicus. As a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl). In combination with ERT for Pompe disease. View all ». Aug 5, 2015. Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates. Jul 29, 2015. View all ».

ir.amphastar.com ir.amphastar.com

Investors - Amphastar Pharmaceuticals, Inc.

Annual Reports and Proxies. We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and branded injectable and inhalation products. We currently manufacture and sell 15 products in the U.S. and are developing a portfolio of 13 generic and 7 branded injectable and inhalation products that primarily target markets with high technical barriers to entry. Leverage our research and development capabilities;. Amphastar...

ir.amriglobal.com ir.amriglobal.com

Investors | Albany Molecular Research

Whitepapers and Trade Articles. Whitepapers and Trade Articles. Albany Molecular Research Inc. Investor Webcast: AMRI Acquires Gadea. Investor Webcast: AMRI Second Quarter Earnings. A Message from Bill Marth. Aug 4, 2015. AMRI Announces Second Quarter 2015 Results. Jul 21, 2015. AMRI to Announce Second Quarter 2015 Results. View all press releases ». Aug 25, 2015. Sep 14, 2015. View all events ». Albany Molecular Research Inc. provides global contract research and manufacturing services to the pharma...

ir.amsc.com ir.amsc.com

Investor Relations | American Superconductor Corporation

Skip to main navigation. Generator and Drivetrain Solutions. Network Planning and Applications. Solar Inverter and Plant Solutions. Turbine Controls and Systems. Utility Reactive Power Solutions. Mar 30, 2018. CBS 60 Minutes segment on The Great Brain Robbery, featuring an interview with CEO, Dan McGahn. Feb 21, 2018. AMSC Announces $10 Million in D-VAR System Orders. D-VAR Systems Sales Expand into Mexico to Support Renewable Connectivity Applications and into Japan for Industrial Power Quality. AMSC to...

ir.amtrustgroup.com ir.amtrustgroup.com

Investor Relations - AmTrust Financial Services

News, Financial Releases. Warranty and Specialty Risk. AmTrust is a multinational property and casualty insurer specializing in coverage for small businesses. We offer workers compensation insurance, extended warranty coverage, specialty middle-market property and casualty insurance and a host of related products and services. Gross Written Premiums. $ in Billions. Net Operating Earnings Per Share. Aug 5, 2015. Aug 4, 2015. Aug 4, 2015 at 10:00 AM ET. Jun 10, 2015 at 10:00 AM CT. News, Financial Releases.

ir.amuse.co.jp ir.amuse.co.jp

株式会社 アミューズ

3/30(金)より 美しいぼろ布展 都築響一が見たBORO を開催. AmuseLantis Europe S.A.S. IR支援会社の株式会社オプティア が運営している、個人投資家向け企業情報ポータル equity story に弊社IR担当者のインタビューが掲載されています。 株主優待 抽選招待 のご案内 を、普通郵便で発送致しました。 弊社執行役員、アミューズシンガポール社長の宮野治彦によるコラム アジア エンタメ川柳 第1句 第37句をアップしました。